6550--Blood Control Reagents
Closed Solicitation Posted
- Solicitation number
- 36C25625Q1470
- Agency
- Veterans Integrated Service Network 16 Veterans Health Administration, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- Shreveport LA 71101
- Points of contact
-
- Eugene Jackson eugene.jackson2@va.gov (713) 791-1414
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 16 is procuring blood control reagents through solicitation 36C25625Q1470. This combined synopsis/solicitation seeks brand name or equal products from original equipment manufacturer Werfen for use at the Overton Brooks VA Medical Center in Shreveport, Louisiana. The procurement follows simplified acquisition procedures for commercial items under FAR Part 13 and will result in a Lowest Price Technically Acceptable (LPTA) award. The solicitation is unrestricted and open market with NAICS code 325413 (In-Vitro Diagnostic Substance Manufacturing) and a size standard of 1,250 employees. Questions were due by September 9, 2025 at 3:00 PM CST, and quotes must be submitted electronically to Contract Specialist Eugene Jackson by September 12, 2025 at 3:00 PM CST.
This procurement does not utilize any set-aside designations and is open to all qualified vendors. While no specific award values or budget ranges are disclosed, the contract structure includes Contract Line Item Numbers (CLINs) 0001-4026, all specified as brand name or equal products from Werfen. The performance period spans five years total, beginning with a base year from September 25, 2025 through September 24, 2026, followed by four optional 12-month periods extending through September 24, 2030. Performance will take place at the Overton Brooks VA Medical Center located at 510 E. Stoner Avenue, Basement BE 30, Shreveport, Louisiana 71101. An amendment was issued to clarify that Anti-M reagent appeared as a duplicate line item in error and should be counted as only one CLIN.
Notice text
2 versions
Update #2 · Latest ·
RFQ 36C25625Q1470 Question and Answer Reponses
The purpose of this amendment is to:
Clarify that this requirement is LPTA for brand name or equal to products.
Clarify that all CLIN 0001-4026 are all brand name or equal to products and the OEM for the CLINs listed is Werfen.
Address the questions submitted in response to the solicitation question deadline of 3pm 09/09/2025. See below
Vendor 1:
Question: Would it be possible to provide the manufacturer for the items on the subject RFQ as we can likely assist however, I am not able to find the source?
Government Response: The OEM for the items listed in the CLIN section is Werfen.
Vendor 2:
Question: *Page 72 of 128 of the solicitation, Anti-M reagent appears twice, is this a duplicate or is it required?
Government Response: This was an accidental duplication. Anti-M is only one CLIN, not two separate CLINs
Update #1 ·
A.1 COMBINED SYNOPSIS/SOLICITATION
1. This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, in conjunction with FAR Part 13, Simplified Acquisition Procedures for Certain Commercial Items as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested, and a written solicitation will not be issued. This shall result in a Lowest-Priced Technically Acceptable Award (LPTA).
2. The combined synopsis/solicitation number is 36C25625Q1470.
3. Solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular FAC 2025-05 (eff. 06/11/2025)
4. This requirement is Unrestricted Open Market. The North American Industry Classification System number is 325413 with a size standard of 1,250.
5. Place of Performance:
Overton Brooks VA Medical Center
510 E. Stoner Avenue,
Basement BE 30
Shreveport LA, 71101
6. Period of Performance:
Period of Performance: The period of performance shall be for one (1) Base Year of 12 months and four (4) 12-month optional performance periods. The Period of Performance reads as follows:Â
Base Year September 25th, 2025 thru September 24th, 2026
Option 1 September 25th, 2025 thru September 24th, 2027
Option 2 September 25th, 2027 thru September 24th, 2028
Option 3 September 25th, 2028 thru September 24th, 2029
Option 4 September 25th, 2029 thru September 24th, 2030
7. All questions regarding this solicitation shall be submitted via email to the Contract Specialist, Eugene Jackson at Eugene.Jackson2@va.gov no later than 3:00PM CST on 09 SEP 2025. Please ensure you ask ALL questions.
8. Quotes are due no later than 12 SEP 2025 at 3:00PM CST and shall be submitted electronically via e-mail to the Contract Specialist, Eugene Jackson at eugene.jackson2@va.gov .
APPLICABLE Provisions and Clauses:
The provision at 52.212-1 Introduction to Offerors Commercial, applies to this acquisition.
The provision at 52.212-2 EVALUATION COMMERCIAL ITEMS (JAN 1999) applies to this acquisition.
Attachments
| File | Type | Posted |
|---|---|---|
| SF-30 Amendment.pdf | ||
| 36C25625Q1470 0001_1.docx | DOCX document | |
| 36C25625Q1470_1.docx | DOCX document |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity